Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CARDINAL HEALTH, INC.

(CAH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cardinal Health : DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT (Form 8-K)

07/22/2021 | 06:58am EDT

DISTRIBUTORS ANNOUNCE PROPOSED OPIOID SETTLEMENT AGREEMENT

07/21/2021

CONSHOHOCKEN, Pa. & DUBLIN, Ohio & IRVING, Texas -- AmerisourceBergen (NYSE: ABC), Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK) announced today that they have negotiated a comprehensive proposed settlement agreement which, if all conditions are satisfied, would result in the settlement of a substantial majority of opioid lawsuits filed by state and local governmental entities.

While the companies strongly dispute the allegations made in these lawsuits, they believe the proposed settlement agreement and settlement process it establishes, which is outlined below, are important steps toward achieving broad resolution of governmental opioid claims and delivering meaningful relief to communities across the United States. The companies remain deeply concerned about the impact the opioid epidemic is having on individuals, families, and communities across the nation and are committed to being part of the solution.

The proposed settlement agreement is the result of years of negotiation with state attorneys general and representatives of the subdivisions. If the proposed settlement agreement and settlement process leads to final settlement through the process outlined below, it would collectively provide thousands of communities across the United States up to approximately $21 billion over 18 years. It would also establish a clearinghouse that consolidates data from all three distributors, which will be available to the settling states to use as part of their anti-diversion efforts.

Subject to certain future milestones described below and the level of participation, the companies would be responsible for up to the following contributions, payable over 18 years:

AmerisourceBergen: $6.4 billion

Cardinal Health: $6.4 billion

McKesson: $7.9 billion

The proposed settlement agreement would become binding only if all conditions outlined below are satisfied:

Approval of State and Territorial Participation For the next 30 days, all U.S. States, territories and Washington DC will have the opportunity to join the settlement, except West Virginia which settled previously with the companies. After the conclusion of the state sign-on period, each company will independently determine whether a sufficient number of states have joined to warrant continuing with the political subdivision sign-on period.
Approval of Political Subdivision Participation If the distributors decide that sufficient states have joined, each participating state will continue to offer its political subdivisions, including those that have not sued, the opportunity to participate in the settlement for an additional 120-day period. After the conclusion of the political subdivision sign-on period, each company will independently determine whether a sufficient number of states and a sufficient number of political subdivisions have joined for the settlement to proceed to implementation.

If the conditions are satisfied, the settlement would become effective 60 days after the distributors determine that there is sufficient participation to proceed. During this 60-day period, the participating states and the distributors would cooperate to obtain consent judgments in each participating state embodying the terms of the settlement. The companies will make their first annual settlement payment into escrow on or before September 30, 2021, and the payment will be disbursed following the effective date, or returned to distributors if the settlement does not become effective.

If, however, a settlement cannot be finalized and plaintiffs instead choose to pursue their claims in court, the companies will continue to assert their strong legal defenses in pending litigation.

This settlement process only addresses the claims of U.S. state attorneys general and political subdivisions in participating states. The West Virginia subdivisions and Native American tribes are not part of this settlement process.

Cautionary Statements Regarding Forward Looking Statements

The preceding descriptions of a potential resolution of certain governmental entities' opioids-related claims against pharmaceutical distribution companies constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the companies undertake no obligation to publicly update forward-looking statements. Risk factors include, but are not limited to: the settlement process may not result in a resolution of all or any claims against each company regarding its role in distributing opioids; the companies may continue to experience costly and disruptive legal disputes and settlements related to distribution of controlled substances, including opioids; the companies might experience losses not covered by insurance; and the companies might be adversely impacted by changes in tax legislation or challenges to their respective tax positions. Investors should read the important risk factors described in each company's Form 10-K, Form 10-Q and Form 8-K reports filed with the Securities and Exchange Commission.

About AmerisourceBergen

AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency and reliability for human and animal health. Our 41,000 global team members power our purpose: We are united in our responsibility to create healthier futures.

About Cardinal Health

Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

About McKesson Corporation

McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful - all for the better health of patients. McKesson has been named a 'Most Admired Company' in the healthcare wholesaler category by FORTUNE, a 'Best Place to Work' by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com.

Contacts

AmerisourceBergen

Investor Contact:

Bennett S. Murphy

610-727-3693

bmurphy@amerisourcebergen.com

Media Contact:

Gabe Weissman

610-727-3696

gweissman@amerisourcebergen.com

Cardinal Health

Investor Contact:

Kevin Moran

614-757-7942

kevin.moran@cardinalhealth.com

Media Contact:

Erich Timmerman

847-887-1487

Erich.Timmerman@cardinalhealth.com

McKesson

Investor Contact:

Holly Weiss

972-969-9174

Holly.Weiss@McKesson.com

Media Contact:

David Matthews

214-952-0833

David.Matthews@McKesson.com

Disclaimer

Cardinal Health Inc. published this content on 22 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 July 2021 10:57:06 UTC.


ę Publicnow 2021
All news about CARDINAL HEALTH, INC.
09/23CARDINAL HEALTH : Harnessing the power of technology to reimagine healthcare delivery
PU
09/23CARDINAL HEALTH : 2021 Proxy Statement
PU
09/22CARDINAL HEALTH : reinvents hospital claims remittance with comprehensive approach
PU
09/14Cardinal Health to Seek M&A
CI
09/14CARDINAL HEALTH : 2021 Annual Report (PDF 2.17 MB)
PU
09/06GLOBAL MARKETS LIVE : Puma, Boeing, Holcim, Revolut, Amazon...
09/06ABC, CAH, MCK - Distributors Announce Proposed Opioid Settlement Will Proceed to Next P..
AQ
09/04Drug companies say enough U.S. states join $26 billion opioid settlement to proceed
RE
09/04MCKESSON, AMERISOURCEBERGEN, CARDINA : Letters reviewed by reuters
RE
08/31CARDINAL HEALTH : Supporting Pelotonia's goal to fund equitable cancer research
PU
More news
Analyst Recommendations on CARDINAL HEALTH, INC.
More recommendations
Financials (USD)
Sales 2022 173 B - -
Net income 2022 1 317 M - -
Net Debt 2022 1 272 M - -
P/E ratio 2022 11,4x
Yield 2022 3,90%
Capitalization 14 917 M 14 917 M -
EV / Sales 2022 0,09x
EV / Sales 2023 0,08x
Nbr of Employees 46 827
Free-Float 88,8%
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | CAH | US14149Y1082 | MarketScreener
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 51,36 $
Average target price 57,23 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Michael C. Kaufmann Chief Executive Officer & Director
Jason M. Hollar Chief Financial Officer
Gregory B. Kenny Independent Non-Executive Chairman
Brian S. Rice Chief Information Officer & Executive VP
Jessica L. Mayer Chief Compliance & Legal Officer
Sector and Competitors